Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: A children's oncology group report

Rodney R. Miles, Mitchell S. Cairo, Prakash Satwani, David L. Zwick, Mark A. Lones, Richard Sposto, Minnie Abromovitch, Sheryl Tripp, Anne L. Angiolillo, Elizabeth Roman, Virginia Davenport, Sherrie L. Perkins

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Immunophenotypic analysis can identify protein epitopes in non-Hodgkin lymphomas (NHL) that may respond to targeted immunotherapies, such as anti-CD20 and anti-CD52. Recent studies suggest additional targets may provide therapeutic benefits in NHL. This study evaluated protein expression of CD25, CD52, CD74 and CD80 in paediatric NHL to determine possible targets for immune-based therapeutic approaches. Patient samples were derived from paediatric NHL clinical trials sponsored by the Children's Cancer Group (CCG, now the Children's Oncology Group, COG) and included Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), disseminated T- and B-cell lymphoblastic lymphoma (T-LBL and B-LBL) and anaplastic large cell (ALCL). Immunophenotypic studies were performed on formalin-fixed, paraffin-embedded diagnostic tissues. CD25 was expressed in 8% of T-LBL and 75% of ALCL cases, but not in BL, DLBCL, or B-LBL. CD52 was expressed in 99% of cases of paediatric NHL of all subtypes. CD74 was expressed in 100% of B-LBL, BL and DLBCL, but was absent in ALCL and T-LBL. CD80 was expressed in 12% of B-LBL, 6% of BL and 10% of DLBCL cases studied, but was not detected in T-cell NHL. These expression patterns suggest that CD25, CD52 and CD74 may represent potential new therapeutic targets in paediatric NHL.

Original languageEnglish (US)
Pages (from-to)506-512
Number of pages7
JournalBritish Journal of Haematology
Volume138
Issue number4
DOIs
StatePublished - Aug 1 2007

Fingerprint

Non-Hodgkin's Lymphoma
Pediatrics
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
T-Cell Lymphoma
B-Cell Lymphoma
Therapeutics
B-Lymphocytes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Paraffin
Immunotherapy
Formaldehyde
Epitopes
Proteins
Clinical Trials
Neoplasms

Keywords

  • Immunohistochemistry
  • Immunophenotype
  • Immunotherapy
  • Lymphoma
  • Paediatric

ASJC Scopus subject areas

  • Hematology

Cite this

Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas : A children's oncology group report. / Miles, Rodney R.; Cairo, Mitchell S.; Satwani, Prakash; Zwick, David L.; Lones, Mark A.; Sposto, Richard; Abromovitch, Minnie; Tripp, Sheryl; Angiolillo, Anne L.; Roman, Elizabeth; Davenport, Virginia; Perkins, Sherrie L.

In: British Journal of Haematology, Vol. 138, No. 4, 01.08.2007, p. 506-512.

Research output: Contribution to journalArticle

Miles, RR, Cairo, MS, Satwani, P, Zwick, DL, Lones, MA, Sposto, R, Abromovitch, M, Tripp, S, Angiolillo, AL, Roman, E, Davenport, V & Perkins, SL 2007, 'Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: A children's oncology group report', British Journal of Haematology, vol. 138, no. 4, pp. 506-512. https://doi.org/10.1111/j.1365-2141.2007.06689.x
Miles, Rodney R. ; Cairo, Mitchell S. ; Satwani, Prakash ; Zwick, David L. ; Lones, Mark A. ; Sposto, Richard ; Abromovitch, Minnie ; Tripp, Sheryl ; Angiolillo, Anne L. ; Roman, Elizabeth ; Davenport, Virginia ; Perkins, Sherrie L. / Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas : A children's oncology group report. In: British Journal of Haematology. 2007 ; Vol. 138, No. 4. pp. 506-512.
@article{118d0c2ff32a456dbdd7d8a21fd34b36,
title = "Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: A children's oncology group report",
abstract = "Immunophenotypic analysis can identify protein epitopes in non-Hodgkin lymphomas (NHL) that may respond to targeted immunotherapies, such as anti-CD20 and anti-CD52. Recent studies suggest additional targets may provide therapeutic benefits in NHL. This study evaluated protein expression of CD25, CD52, CD74 and CD80 in paediatric NHL to determine possible targets for immune-based therapeutic approaches. Patient samples were derived from paediatric NHL clinical trials sponsored by the Children's Cancer Group (CCG, now the Children's Oncology Group, COG) and included Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), disseminated T- and B-cell lymphoblastic lymphoma (T-LBL and B-LBL) and anaplastic large cell (ALCL). Immunophenotypic studies were performed on formalin-fixed, paraffin-embedded diagnostic tissues. CD25 was expressed in 8{\%} of T-LBL and 75{\%} of ALCL cases, but not in BL, DLBCL, or B-LBL. CD52 was expressed in 99{\%} of cases of paediatric NHL of all subtypes. CD74 was expressed in 100{\%} of B-LBL, BL and DLBCL, but was absent in ALCL and T-LBL. CD80 was expressed in 12{\%} of B-LBL, 6{\%} of BL and 10{\%} of DLBCL cases studied, but was not detected in T-cell NHL. These expression patterns suggest that CD25, CD52 and CD74 may represent potential new therapeutic targets in paediatric NHL.",
keywords = "Immunohistochemistry, Immunophenotype, Immunotherapy, Lymphoma, Paediatric",
author = "Miles, {Rodney R.} and Cairo, {Mitchell S.} and Prakash Satwani and Zwick, {David L.} and Lones, {Mark A.} and Richard Sposto and Minnie Abromovitch and Sheryl Tripp and Angiolillo, {Anne L.} and Elizabeth Roman and Virginia Davenport and Perkins, {Sherrie L.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1111/j.1365-2141.2007.06689.x",
language = "English (US)",
volume = "138",
pages = "506--512",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas

T2 - A children's oncology group report

AU - Miles, Rodney R.

AU - Cairo, Mitchell S.

AU - Satwani, Prakash

AU - Zwick, David L.

AU - Lones, Mark A.

AU - Sposto, Richard

AU - Abromovitch, Minnie

AU - Tripp, Sheryl

AU - Angiolillo, Anne L.

AU - Roman, Elizabeth

AU - Davenport, Virginia

AU - Perkins, Sherrie L.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Immunophenotypic analysis can identify protein epitopes in non-Hodgkin lymphomas (NHL) that may respond to targeted immunotherapies, such as anti-CD20 and anti-CD52. Recent studies suggest additional targets may provide therapeutic benefits in NHL. This study evaluated protein expression of CD25, CD52, CD74 and CD80 in paediatric NHL to determine possible targets for immune-based therapeutic approaches. Patient samples were derived from paediatric NHL clinical trials sponsored by the Children's Cancer Group (CCG, now the Children's Oncology Group, COG) and included Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), disseminated T- and B-cell lymphoblastic lymphoma (T-LBL and B-LBL) and anaplastic large cell (ALCL). Immunophenotypic studies were performed on formalin-fixed, paraffin-embedded diagnostic tissues. CD25 was expressed in 8% of T-LBL and 75% of ALCL cases, but not in BL, DLBCL, or B-LBL. CD52 was expressed in 99% of cases of paediatric NHL of all subtypes. CD74 was expressed in 100% of B-LBL, BL and DLBCL, but was absent in ALCL and T-LBL. CD80 was expressed in 12% of B-LBL, 6% of BL and 10% of DLBCL cases studied, but was not detected in T-cell NHL. These expression patterns suggest that CD25, CD52 and CD74 may represent potential new therapeutic targets in paediatric NHL.

AB - Immunophenotypic analysis can identify protein epitopes in non-Hodgkin lymphomas (NHL) that may respond to targeted immunotherapies, such as anti-CD20 and anti-CD52. Recent studies suggest additional targets may provide therapeutic benefits in NHL. This study evaluated protein expression of CD25, CD52, CD74 and CD80 in paediatric NHL to determine possible targets for immune-based therapeutic approaches. Patient samples were derived from paediatric NHL clinical trials sponsored by the Children's Cancer Group (CCG, now the Children's Oncology Group, COG) and included Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), disseminated T- and B-cell lymphoblastic lymphoma (T-LBL and B-LBL) and anaplastic large cell (ALCL). Immunophenotypic studies were performed on formalin-fixed, paraffin-embedded diagnostic tissues. CD25 was expressed in 8% of T-LBL and 75% of ALCL cases, but not in BL, DLBCL, or B-LBL. CD52 was expressed in 99% of cases of paediatric NHL of all subtypes. CD74 was expressed in 100% of B-LBL, BL and DLBCL, but was absent in ALCL and T-LBL. CD80 was expressed in 12% of B-LBL, 6% of BL and 10% of DLBCL cases studied, but was not detected in T-cell NHL. These expression patterns suggest that CD25, CD52 and CD74 may represent potential new therapeutic targets in paediatric NHL.

KW - Immunohistochemistry

KW - Immunophenotype

KW - Immunotherapy

KW - Lymphoma

KW - Paediatric

UR - http://www.scopus.com/inward/record.url?scp=34447309307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447309307&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06689.x

DO - 10.1111/j.1365-2141.2007.06689.x

M3 - Article

C2 - 17659054

AN - SCOPUS:34447309307

VL - 138

SP - 506

EP - 512

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -